PROSPECT: This is an observational study and is designed to describe the clinical outcomes and the burden of disease in PD patients with motor fluctuations not adequately controlled by current PD medications.
The objective of the Corrona Psoriasis Registry is to create a national database of patients with psoriasis. Data collected will be used to study the disease and to evaluate the effectiveness and safety of medications approved for the treatment of psoriasis.
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of the investigational drug, dipraglurant (ADX48621), in subjects with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID).
ANNEXa-1 (18-513): This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracerebral hemorrhage within 6 hours of symptom onset (from the baseline scan) and within 15 hours of taking an oral FXa inhibitor (from randomization). The study will use a prospective, randomized, open-label design, as it is unfeasible to blind the Investigator to the treatment assignment given the many potential therapeutic options available under usual care treatment.
The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy. Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.
PADOVA: The purpose of this study is to find out what effects, good and/or bad, prasinezumab versus placebo has on Parkinson’s disease in people who are taking standard medication to manage the disease symptoms.